The Efficacy and Safety of GCWB104 ( Flos Lonicera Extract) in Functional Dyspepsia: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study

Yonghoon Choi, Nayoung Kim, Gi Tark Noh, Ju Yup Lee, Dong Ho Lee, Yonghoon Choi, Nayoung Kim, Gi Tark Noh, Ju Yup Lee, Dong Ho Lee

Abstract

Background/Aims: The Flos Lonicera extract GCWB104 has been shown to have significant protective effects against gastritis and gastric ulcers in vivo. The aim of this study was to investigate the efficacy and safety of GCWB104 in subjects with functional dyspepsia (FD). Methods: In this single-center, double-blind, randomized clinical trial, 92 subjects diagnosed with FD using the Rome III criteria were allocated to either the test group (300 mg of GCWB104, containing 125 mg of Flos Lonicera extract, twice daily) or the placebo group (300 mg placebo, twice daily). The total score improvement on the Gastrointestinal Symptom Rating Scale (GSRS) for individual symptoms, changes in antioxidant levels, changes in dyspepsia-related quality of life according to the Nepean Dyspepsia Index (NDI), and adverse effects were compared before and after 8 weeks of treatment. Results: The differences in total GSRS scores and score improvements after 8 weeks of treatment were significant between the GCWB104 and control groups (p=0.0452 and p=0.0486, respectively). Thirteen of 15 individual symptoms on the GSRS improved in the GCWB104 group, while six symptoms improved in the control group. In addition, statistically significant changes in rumbling, loose stool, and stool urgency were observed in the GCWB104 group. Blood 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels, known as antioxidants, showed significant reductions after 8 weeks of administration of GCWB104. There were no adverse events related to treatment with GCWB104. Conclusions: GCWB104 safely contributed to improvements in mild to moderate FD and irritable bowel syndrome symptoms. Antioxidant effects of GCWB104 were also suggested (Clinicaltrials.gov number NCT04008901).

Keywords: Antioxidant; Dyspepsia; Lonicera.

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Flowchart showing enrolled subjects and dropouts from the study. Adverse reaction definitely related to study drug: rash (n=1). Adverse reactions not related to study drug: musculoskeletal pain (n=1), dyspepsia (n=1) and nasal obstruction (n=1). ITT, intention-to-treat; PP, per protocol.

References

    1. Knill-Jones RP. Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol Suppl. 1991;182:17–24. doi: 10.3109/00365529109109532.
    1. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466–1479. doi: 10.1053/j.gastro.2005.11.059.
    1. Kim SE, Kim N, Lee JY, et al. Prevalence and risk factors of functional dyspepsia in health check-up population: a nationwide multicenter prospective study. J Neurogastroenterol Motil. 2018;24:603–613. doi: 10.5056/jnm18068.
    1. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology. 2004;127:1239–1255. doi: 10.1053/j.gastro.2004.05.030.
    1. Choi MG, Jung HK. Health related quality of life in functional gastrointestinal disorders in Asia. J Neurogastroenterol Motil. 2011;17:245–251. doi: 10.5056/jnm.2011.17.3.245.
    1. Oh KH, Nam Y, Jeong JH, Kim IK, Sohn UD. The effect of DA-9701 on 5-hydroxytryptamine-induced contraction of feline esophageal smooth muscle cells. Molecules. 2014;19:5135–5149. doi: 10.3390/molecules19045135.
    1. Li Y, Cai W, Weng X, et al. Lonicerae japonicae flos and Lonicerae flos: a systematic pharmacology review. Evid Based Complement Alternat Med. 2015;2015 905063.
    1. Bang BW, Park D, Kwon KS, et al. BST-104, a water extract of Lonicera Japonica, has a gastroprotective effect via antioxidant and anti-inflammatory activities. J Med Food. 2019;22:140–151. doi: 10.1089/jmf.2018.4231.
    1. Jung DH, Choi EJ, Jeon HH, Lee YH, Park H. Effects of GC7101, a novel prokinetic agent on gastric motor function: ex vivo study. J Neurogastroenterol Motil. 2014;20:469–474. doi: 10.5056/jnm14010.
    1. Kang JW, Lee SM. Protective effects of chlorogenic acid against experimental reflux esophagitis in rats. Biomol Ther (Seoul) 2014;22:420–425. doi: 10.4062/biomolther.2014.066.
    1. Ku SK, Seo BI, Park JH, et al. Effect of Lonicerae flos extracts on reflux esophagitis with antioxidant activity. World J Gastroenterol. 2009;15:4799–4805. doi: 10.3748/wjg.15.4799.
    1. Rodríguez I, Illnait J, Terry H, et al. Effects of Abexol (beeswax alcohols) on gastrointestinal symptoms in middle-aged and older subjects. Revista CENIC Ciencias Biologicas. 2019;40:147–154.
    1. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046–1052. doi: 10.3109/00365529509101605.
    1. Tsai MC, Huang TL. Thiobarbituric acid reactive substances (TBARS) is a state biomarker of oxidative stress in bipolar patients in a manic phase. J Affect Disord. 2015;173:22–26. doi: 10.1016/j.jad.2014.10.045.
    1. Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373:1853–1863. doi: 10.1056/NEJMra1501505.
    1. Holtmann G, Talley NJ. Herbal medicines for the treatment of functional and inflammatory bowel disorders. Clin Gastroenterol Hepatol. 2015;13:422–432. doi: 10.1016/j.cgh.2014.03.014.
    1. Kwon YS, Son M. DA-9701: a new multi-acting drug for the treatment of functional dyspepsia. Biomol Ther (Seoul) 2013;21:181–189. doi: 10.4062/biomolther.2012.096.
    1. Holtmann G, Adam B, Vinson B. Evidence-based medicine and phytotherapy for functional dyspepsia and irritable bowel syndrome: a systematic analysis of evidence for the herbal preparation Iberogast. Wien Med Wochenschr. 2004;154:528–534. doi: 10.1007/s10354-004-0119-3.
    1. Suzuki H, Matsuzaki J, Fukushima Y, et al. Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia. A multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterol Motil. 2014;26:950–961. doi: 10.1111/nmo.12348.
    1. Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast®): a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163:65–72. doi: 10.1007/s10354-012-0169-x.
    1. von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007;102:1268–1275. doi: 10.1111/j.1572-0241.2006.01183.x.
    1. Jo SY, Hussain Z, Lee YJ, Park H. Corticotrophin-releasing factor-mediated effects of DA-9701 in postoperative ileus guinea pig model. Neurogastroenterol Motil. 2018;30:e13385. doi: 10.1111/nmo.13385.
    1. Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011;106:421–431. doi: 10.1038/ajg.2010.458.
    1. Lamprecht M, Bogner S, Schippinger G, et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr. 2012;9:45. doi: 10.1186/1550-2783-9-45.
    1. Maki KC, Reeves MS, Farmer M, et al. Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults. J Nutr. 2009;139:264–270. doi: 10.3945/jn.108.098293.
    1. Lambert MNT, Thorup AC, Hansen ESS, Jeppesen PB. Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms. PLoS One. 2017;12:e0176590. doi: 10.1371/journal.pone.0176590.
    1. Lee HH, Jung HK, Choi MG. Guideline recommendation for endpoints used in clinical trials for functional dyspepsia. Korean J Gastroenterol. 2018;72:170–178. doi: 10.4166/kjg.2018.72.4.170.
    1. Ford AC, Luthra P, Tack J, Boeckxstaens GE, Moayyedi P, Talley NJ. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017;66:411–420. doi: 10.1136/gutjnl-2015-310721.
    1. Yang YJ, Bang CS, Baik GH, et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol. 2017;17:83. doi: 10.1186/s12876-017-0639-0.
    1. Wu D, Liu B, Yin J, et al. Detection of 8-hydroxydeoxyguanosine (8-OHdG) as a biomarker of oxidative damage in peripheral leukocyte DNA by UHPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1064:1–6. doi: 10.1016/j.jchromb.2017.08.033.
    1. Kauppi J, Räsänen J, Sihvo E, et al. Increased oxidative stress in the proximal stomach of patients with Barrett’s esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Transl Oncol. 2016;9:336–339. doi: 10.1016/j.tranon.2016.06.004.
    1. Albayrak F, Uyanik MH, Dursun H, et al. Should increased levels of urinary 8-hydroxydeoxyguanosine in chronic gastritis imply intestinal metaplasia or gastric atrophy? South Med J. 2010;103:753–757. doi: 10.1097/SMJ.0b013e3181e6d55d.
    1. Du LJ, Chen BR, Kim JJ, Kim S, Shen JH, Dai N. Helicobacter pylori eradication therapy for functional dyspepsia: systematic review and meta-analysis. World J Gastroenterol. 2016;22:3486–3495. doi: 10.3748/wjg.v22.i12.3486.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться